|
業務類別
|
Biotechnology |
|
業務概覽
|
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33. |
| 公司地址
| 1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014 |
| 電話號碼
| +1 702 825-9872 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.zurabio.com |
| 員工數量
| 40 |
| Ms. Kimberly Ann Davis |
Chief Operating Officer, Secretary and Chief Legal Officer |
美元 486.36K |
26/01/2026 |
| Dr. Gary Whale, PhD |
Chief Technology Officer |
-- |
30/04/2026 |
| Dr. Sandeep C. Kulkarni, M.D. |
Director and Chief Executive Officer |
-- |
26/01/2026 |
| Dr. Kiran Nistala, M.B.B.S.,PhD |
Chief Medical Officer and Head, Development |
美元 468.33K |
30/04/2026 |
| Ms. Marlyn Mathew |
Principal Financial Officer, Principal Accounting Officer, Vice President, Finance and Accounting |
-- |
23/04/2026 |
|
|
| Mr. Amit D. Munshi |
Chairman of the Board |
30/04/2026 |
| Ms. Jennifer Ann Jarrett |
Independent Director |
30/04/2026 |
| Dr. Daniel Becker, M.D.,PhD |
Independent Director |
30/04/2026 |
| Dr. Mark Eisner, M.D.,M.P.H. |
Director |
23/02/2026 |
| Mr. Steven J. Schoch |
Independent Director |
30/04/2026 |
| Dr. Sandeep C. Kulkarni, M.D. |
Director and Chief Executive Officer |
26/01/2026 |
| Mr. Parvinder Thiara |
Director |
26/01/2026 |
| Dr. Ajay Nirula, M.D.,PhD |
Director |
23/02/2026 |
|
|
|
|
